More About Julie
Julie Yoo is a General Partner on the Bio + Health team, where she leads investments in companies that are transforming how we access, pay for, and experience healthcare. Her portfolio includes AKASA, Ambience, Bayesian Health, Bold Health, Firefly Health, Hippocratic AI, Marker Learning, Marley, Patina, Season Health, Sprinter Health, Thatch Health, Tomorrow Health, Topography, Turquoise Health and Zus Health. She is also a member of the Board of Directors at Bassett Healthcare Network.
Prior to joining Andreessen Horowitz, Julie was the cofounder and Chief Product Officer of Kyruus, a VC-backed healthtech company where she helped build and scale the business from 0 to 20M patients and over 225,000 healthcare providers across the US using their platform. Before that, Julie was VP of Product at Generation Health (acquired by CVS Health) and a Product Manager at Knome. Julie’s tech career began as an early member of the software engineering team at Endeca Technologies, which was acquired by Oracle.
Julie studied computer science and pre-medicine as an undergrad at MIT and obtained an MS in genomics from Harvard-MIT HST and an MBA from MIT Sloan. Julie is a Young Global Leader with the World Economic Forum and has been recognized through numerous awards and honors from Midas Brink List, Becker’s Hospital Review, Health Data Management, MedTech Boston, and Rock Health.
Latest Content
-
Ankit Jain, CEO and cofounder of Infinitus Systems, Inc, joins Julie Yoo, a16z Bio + Health general partner, to discuss Infinitus's work in solving one of healthcare's most pressing challenges: workforce shortages. Lever...
-
Alexander Saint-Amand, cofounder and CEO of Topography, reflects on his journey from leading Gerson Lehrman Group (GLG), a pioneer in expert networks, to tackling systemic barriers in clinical trials at his current compa...
-
In the “Maslow's hierarchy” of the healthcare industry’s needs, the infrastructure layer is the foundational workhorse of the system. Healthtech infrastructure refers to the utilities and systems-of-record that underpin all of the core operational transactions, financial transactions, data exchange, and interoperability actions that occur across the healthcare system everyday.
-
Healthcare is a $4 trillion industry, making up nearly a fifth of the U.S. economy—but despite having some of the best doctors and advanced technology, the system often delivers poor outcomes at skyrocketing costs. Why i...
-
Hippocratic AI cofounder and CEO Munjal Shah joins a16z Bio + Health general partner Julie Yoo to explore the incredible potential of generative AI in transforming healthcare delivery.
-
Jeff Margolis, founder of TriZetto, joins Julie Yoo, a16z Bio + Health general partner, to share the journey of building an iconic company in healthcare infrastructure. From the early days of managed care to creating a t...
-
As we prepare to step into 2025, the possibilities for applied AI are reshaping industries in profound ways.
-
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
-
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
-
Consumers are effectively a new class of payor. And a number of opportunities exist to build solutions for those consumers (aka these new “micro payors”) to fund, navigate, and manage their healthcare purchases.
-
Whereas we historically have viewed the low adoption of software as a liability, we now view that as an asset—we don't face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations.
-
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
-
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in 2024. Here in our 3-part series, you’ll hear directly from partners across all our verticals, as we dive even more deeply into these ideas. What’s the why now? Who is already building in these spaces? What opportunities and challenges are on the horizon? And how can you get involved?
-
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
-
While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.
-
As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.
-
At the end of the day, even the best AI models will fail if they don’t figure out a way to achieve broad distribution and profitable monetization, so it’s important to understand the psyche of the buyers and decision makers who will determine the fate of your products.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
Margaret McKenna, former CTO of Devoted Health and our newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Dan Rosenthal, a provider network expert and the newest advisory partner for a16z Bio + Health, joins Julie Yoo, general partner.Together, they talk about the 101 and 201 of provider networks, tactical advice for digital health builders, and how AI could theoretically change the way networks are constructed.
-
The very nature of generative AI—conversational, scalable, accessible to non-technical users—has the potential to solve the shortcomings of previous generations of rules-based chatbots and other such products in making these concepts a reality.
-
Most people don’t need a reminder of the state of healthcare in America. But it’s not just the consumer that’s hurting. Medical debt is increasing, billions are lost in unpaid claims, hospitals are in the red, service prices can range up to 30x…. In this episode, a16z GPs Julie You and David Haber explain where the healthcare system breaks down and how the three party system — between payors, providers, and consumers — can be rethought through the lens of Fintech. Learn more about Healthcare x Fintech here: https://a16z.com/healthcare-meets-fintech/
-
How can digital health founders successfully implement channel partnerships to accelerate the distribution of their products and services? When should they use them? How should they use them? We spoke with the founders of Omada, Ginger, and Cedar, each of which have successfully utilized channel partnerships, and surveyed 36 other digital health startups to analyze the state of channel partnerships in the market today.
-
Today’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani.
-
Today’s episode is with Florian Otto, cofounder and CEO of Cedar. He is joined by a16z Bio + Health general partner Julie Yoo.
-
At a16z, marketplaces represent one of our favorite business models. Our annual Marketplace 100 provides insight into the latest consumer marketplace trends across industries.
-
In this episode, a16z Bio + Health general partner Julie Yoo chats with Bassett Healthcare Network president and CEO Tommy Ibrahim.
-
The public market situation for healthtech can seem pretty depressing. Recently IPOed healthtech stocks are underperforming the broader market, with some falling 95%+ from their IPO—meanwhile, more traditional companies...
-
Every student can learn, just not on the same day, or the same way. – George Evans
-
Consider this: most healthcare providers are flying blind when it comes to their finances.
-
At the end of 2022, our team at a16z asked dozens of partners across the firm to spotlight one big idea that startups in their fields could tackle in 2023. Emerging from this exercise came 40+ builder-worthy pursuits for the year, ranging from entertainment franchise games to precision delivery of medicine to small modular reactors, and of course loads of AI applications. In our 2-part series, we’ll be covering 12 of these big ideas with the partners that shared them. Here in part 2, we’ll cover Fintech, American Dynamism, and Bio & Health. Listen in as we chat with Anish Acharya, Angela Strange, Michelle Volz, Ryan McEntush, Vijay Pande, and Julie Yoo. And for the full list of 40+ ideas, check out the full article: https://a16z.com/2022/12/15/big-ideas-in-tech-2023/
-
In this episode, Paul Keckley, the managing editor of the Keckley Report and a health policy expert, joins Julie Yoo, general partner at a16z, and Olivia Webb, editorial lead at a16z.
-
How are healthtech companies creating sustainable growth paths by selling to SMBs? Can companies solely rely on SMB sales to get to scale, or do they inevitably need to go upmarket (especially during challenging economic times)? We talked to Nancy Ham, the previous CEO of WebPT, Nate Maslak, CEO and cofounder of Ribbon Health, and Oliver Kharraz, CEO and cofounder of ZocDoc, to unpack their SMB-go-to-market strategies. We also surveyed 33 digital health companies that sell to SMBs to gain insight into a broader swath of approaches that upstarts are taking.
-
“The future is already here - it’s just unevenly distributed,” said science fiction writer William Gibson. As much as we hem and haw about the adoption of value-based care being slow, the fact is that it’s already here in various pockets, and in those pockets, it runs deep.
-
Bio + Health general partner Julie Yoo joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, editorial lead, to discuss the consolidated pharmaceutical system.
-
Most of the wildly successful fintech companies haven’t done much in the healthcare sector. Why?
-
Growing up in Seoul, Korea, I used to love shopping at the night markets, where I'd go for the thrill of the chase of a good deal. None of the items were labeled with prices, and many items could be found in multiple sta...
-
COVID has strained our healthcare system, payors are feeling the squeeze of rising costs, and patients are bearing the brunt of the current system's shortcomings. As a result, healthcare is undergoing a transformation, f...
-
'Let thy food be thy medicine and medicine be thy food.' - Hippocrates
-
Supply-demand mismatch problems in healthcare
-
2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...
-
In 2021, financial services continued to have its moment, with fintech fundraising surpassing all years prior. What's in store for 2022?
-
B2C2B — also known as bottom up — has helped companies like Slack, Zoom, Dropbox, and other software companies break into B2B. Now B2C2B is coming to digital health, as a wave of startups are first selling products and s...
-
Primary care, a critical component of our healthcare system, got slammed over the last 20 months. Even before the pandemic, it was on its heels in the face of a fee-for-service reimbursement system biased towards technic...
-
Digital health is currently one of the fastest growing VC-funded segments, and it’s time to update the GTM playbooks for the current (and future) market.
-
Every healthcare company will eventually be a home health company. In the future, providers, payors, and diagnostics companies will find it difficult to compete, and to bear risk in value-based care, without the ability...
Select Investments
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.
